Morphochem and The Genetics Company announce the resolution of the X-ray structure of beta-secretase with a novel inhibitor
The Genetics Company, Inc. and Morphochem AG have announced that they have successfully achieved an important milestone in their research collaboration using Morphochem's structural biology tools to support the beta-secretase program of The Genetics Company.
Morphochem applied its protein expression, purification, crystallization and structure determination capabilities, all part of Morphochem's MOREsystem®, to generate biostructural information for further optimization of inhibitor compounds against beta-secretase identified by The Genetics Company as potential new therapeutic agents for Alzheimer's Disease.
Topics
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Merck KGaA Acquires Rights to PI-2301 Program for Multiple Sclerosis
Category:Flavin_enzymes

Smart MCs Receives Major Australian Government Grant to Establish $600k Advanced Microcarrier Production Line
Category:Molybdenum_enzymes
